Blog
RSS FeedPosted by Michael Wonder on 22 Aug 2025
DoH publishes revised agenda for November 2025 PBAC meeting (version 2)
20 August 2025 - The DoH has published a revised agenda for the November 2025 PBAC meeting. ...
Posted by Michael Wonder on 22 Aug 2025
Leqvio advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance
21 August 2025 - Eligible Canadian patients with heterozygous familial hypercholesterolaemia are one step closer to publicly funded access to ...
Posted by Michael Wonder on 22 Aug 2025
Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE
21 August 2025 - NICE has recommended a new first-line treatment for adults with advanced bladder cancer, marking a significant ...
Posted by Michael Wonder on 16 Aug 2025
Vabysmo (faricimab injection) now publicly funded for macular oedema secondary to retinal vein occlusion and pre-filled syringe in Quebec
15 August 2025 - Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively ...
Posted by Michael Wonder on 14 Aug 2025
Final decision on cerliponase alfa for Batten disease treatment confirmed
14 August 2025 - In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (Brineura; BioMarin) ...
Posted by Michael Wonder on 12 Aug 2025
New and expanded PBS listings for endometrial cancer, neuroblastoma, Parkinson's disease and melanoma
11 August 2025 - Australians with Parkinson’s disease, neuroblastoma, endometrial cancer, cystic fibrosis and melanoma will have access to new ...
Posted by Michael Wonder on 11 Aug 2025
SMC - August 2025 decisions
11 August 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 11 Aug 2025
PHARMAC to update access and supply of COVID-19 treatments
11 August 2025 - Pharmac will simplify the criteria for people accessing COVID-19 anti-viral medicines and will align the funding ...
Posted by Michael Wonder on 11 Aug 2025
Trump’s trade war is not the only threat to cheap PBS medicines
10 August 2025 - Australia’s health system is rightly celebrated for its universal access and cost effectiveness, but its outdated assessment ...
Posted by Michael Wonder on 09 Aug 2025
Labor ‘very concerned’ by Trump pharma threat
7 August 2025 - The Albanese Government says it is “very concerned” after Donald Trump’s latest tariff threat on a key ...
Posted by Michael Wonder on 09 Aug 2025
Labor vows to ‘fight’ as Trump threatens pharma tariffs
8 August 2025 - The Albanese government is vowing to “fight for the PBS” as Donald Trump tries to strong-arm ...
Posted by Michael Wonder on 08 Aug 2025
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder and adults with generalised myasthenia gravis
7 August 2025 - The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have ...
Posted by Michael Wonder on 08 Aug 2025
Access to multiple sclerosis treatments inadequate in British Columbia
7 August 2025 - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis, is calling for the provincial ...
Posted by Michael Wonder on 08 Aug 2025
PBS wait times a more urgent issue than Donald Trump's potential pharmaceutical tariffs, peak medicines body warns
7 August 2025 - Excessive wait times for medicines to be listed on the PBS are a much greater threat ...
Posted by Michael Wonder on 06 Aug 2025
NICE approves first immunotherapy combination for endometrial cancer
6 August 2025 - Around 2,100 people with advanced womb cancer are set to benefit from a groundbreaking new treatment option, ...